Share this Page:
Results from a phase 2 clinical trial of axitinib (Inlyta) for patients with advanced non-clear cell renal cell carcinoma (RCC) who had failed prior treatment with temsirolimus (Torisel) are promising in terms of objective response rate (ORR) and progression-free survival (PFS).
Forty patients with metastatic or recurrent non-clear cell RCC who had failed treatment with temsirolimus were treated with axitinib. Most patients had papillary type 2 (60.0%) and most were of intermediate risk (72.5%) of cancer progression/recurrence. Median PFS was 7.4 months, ORR was 37.5%, and the disease control rate was 67.5%. The median overall survival was 12.1 months. Most adverse events were manageable, and there were no unexpected toxicities.
Axitinib showed promising efficacy in terms of ORR and PFS in recurrent or metastatic non-clear cell RCC when used after failure with temsirolimus.
The study was published in the journal Clinical Genitourinary Cancer last month.
